
|Articles|April 1, 2003
- Psychiatric Times Vol 20 No 4
- Volume 20
- Issue 4
First Night On-Call, Coronary Care Unit
Poetry of the Times
Advertisement
I'm driving a knife-edge
mountain ridge at midnight,
no lines, no guard rails,
a semi screaming down my lane
ready to crush me with its cargo
of science I still need to learn.
A rusted out Chevy on my tail
scrapes an exhaust pipe and sends
sparks into darkness, their brief light
fading fast as facts I've memorized.
I don't know who will die tonight,
me or them, but I grip the wheel tight,
knuckles lit white by high-beams,
my own heart pounding, heading uphill,
engine moaning, pedal to the metal.
Articles in this issue
over 23 years ago
Global and Social Considerationsover 23 years ago
Security Alerts Trouble American Psycheover 23 years ago
Psychiatry's Hottest Niche Marketsover 23 years ago
The Last Frontier: Going Beyond the Limitsover 23 years ago
Secondary Traumatization in Mental Health Care Providersover 23 years ago
Changes in the Concept of PTSD and Traumaover 23 years ago
The DSM: Not Perfect, but Better Than the Alternativeover 23 years ago
Dump the DSM>!Advertisement
Related to this article

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.

Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.

Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.

Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.

An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.

Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.

Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Phase 2 Clinical Study Initiated: Evaluating NBI-'567 for the Treatment of Adults With Alzheimer Disease
5

